Journal: Materials

Article Title: The Effects of Light Crystal Display 3D Printers, Storage Time and Steam Sterilization on the Dimensional Stability of a Photopolymer Resin for Surgical Guides: An In Vitro Study

doi: 10.3390/ma18030474

Figure Lengend Snippet: LCD 3D printers: technical specifications.

Article Snippet: Materials and methods: Five test bodies, varying in shape and dimensions, were designed using computer-aided design (CAD) software and manufactured using three different Light Crystal Display (LCD) 3D printers (AccuFab-L4D, Elegoo Mars Pro 3, and Zortrax Inspire).

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Precision Assessment of Facial Asymmetry Using 3D Imaging and Artificial Intelligence

doi: 10.3390/jcm14207172

Figure Lengend Snippet: A 3D facial surface image obtained by the Vectra ® M3 imaging system showing frontal, three-quarter, and profile views.

Article Snippet: Following photographic image capture, achieved within milliseconds, the software program VECTRA ® 3D Analysis Module (VAM version 6.2.3) was used to process a composite 3D surface image.

Techniques: Imaging

Journal: Aesthetic Surgery Journal

Article Title: The Effect of Patient Involvement in Implant Size Selection on Satisfaction With Breast Size: An Analysis of 1840 Primary Augmentations

doi: 10.1093/asj/sjaf085

Figure Lengend Snippet: The Vectra 3D (Canfield Scientific, Parsippany, NJ) system displays a simulation of the expected results, which helps the patient with the final choice of specific breast implants.

Article Snippet: The Vectra 3D system has been proven to be accurate in predicting the volumetric outcomes of breast procedures, achieving >90% accuracy.

Techniques:

Journal: NPJ Precision Oncology

Article Title: IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer

doi: 10.1038/s41698-025-01041-1

Figure Lengend Snippet: A Relative gene expression of IL-6 by quantitative (q)RT-PCR analysis in MCF7 parental (Par) and resistant (Res) cell lines after shRNA knockdown of IL-6 by one of two clones (shIL-6 #1 and shIL-6 #2) or control scrambled shRNA (shSCR). Cells were grown in culture for 3 days. B Relative gene expression of STAT3 by qRT-PCR analysis. C Secreted IL-6 levels measured by ELISA and normalized based on the number of cells (relative concentration [conc]). D Western blot analysis of pSTAT3 (Y705) and total STAT3 after 3 days in culture. E Dose-response curves of treatment with 0.01–12 μM palbociclib for 6 days followed by 6 days of recovery compared with MCF7 Par shSCR. Number of cells/growth was assessed using the crystal violet assay. Data were normalized to DMSO (100%), plotted, and analyzed using nonlinear regression on GraphPad Prism 9. Dashed line and bar graphs depict half-maximal inhibitory concentration (IC 50 ) values. F Dose-response curves after 24 h of estrogen deprivation followed by re-addition of 10 nM beta-estradiol and treatment with varying concentrations (0.01–12 μM) of fulvestrant for 2 days compared with MCF7 Par shSCR. Number of cells/growth was assessed using the crystal violet assay as in panel E. G Dose-response curves with 0.01–12 μM TTI-101 for 3 days followed by 9 days of recovery. Number of cells/growth was assessed using the crystal violet assay as in panel ( E ). H qRT-PCR analysis of estrogen responsive genes—ER and PgR. I qRT-PCR analysis of epithelial-mesenchymal transition (EMT) markers N-cadherin and Vimentin. J qRT-PCR analysis of transcription factors related to breast cancer stem cell-like markers CD44 and ALDH1. K Western blot analysis of estrogen receptor (ERa), PgR, EMT markers, and G1/S transition proteins. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

Article Snippet: Palbociclib isethionate (MedChemExpress) was diluted in 0.5 W/V% methyl cellulose 400 (FUJIFILM Wako Chemicals), TTI-101 was diluted in 60:40 Labrasol:PEG400 with brief sonication for about 2 min, and vehicle was a 50:50 mixture of 0.5 W/V% methyl cellulose 400 and 60:40 Labrasol:PEG400.

Techniques: Gene Expression, Reverse Transcription Polymerase Chain Reaction, shRNA, Knockdown, Clone Assay, Control, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Concentration Assay, Western Blot, Crystal Violet Assay

Journal: NPJ Precision Oncology

Article Title: IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer

doi: 10.1038/s41698-025-01041-1

Figure Lengend Snippet: A , B Dose-response curves in MCF7 and T47D parental (Par) control scrambled shRNA (shSCR), shIL-6 #1, and shIL-6 #2 cells, depicting the effect of treatment with 0.01–12 μM palbociclib for 6 days followed by 6 days of recovery ( A ) and after 24 h of estrogen deprivation followed by re-addition of 10 nM beta-estradiol and treatment with varying concentrations (0.01–12 μM) of fulvestrant for 2 days ( B ). Dashed line depicts half-maximal inhibitor concentration (IC 50 ) values. C , D Bar graphs depicting the average IC 50 values in MCF7 and T47D parental shSCR, shIL-6 #1, and shIL-6 #2 cells treated with palbociclib ( C ) and fulvestrant ( D ) as indicated in A , B. E , F Doubling time every 3 days for 21 days showing the effect of shRNA knockdown of IL-6 on the proliferation of MCF7 and T47D parental cell lines. G , H MCF7 parental ( G ) and T47D ( H ) shSCR, shIL-6 #1, and shIL-6 #2 cells were treated with 1 μM palbociclib every 3 days for 21 days with measurements taken every 3 days as indicated in G for cell growth and IL-6 secreted protein levels (ELISA). I Representative images of senescence-associated ß-galactosidase (SA-βgal) staining in MCF7 parental shSCR, shIL-6 #1, and shIL-6 #2 cells treated with or without 1 μM palbociclib every 3 days for 21 days. Quantification of SA-βgal+ cells was calculated every 3 days relative to number of cells. J Representative images of SA-βgal staining in MCF7 resistant (Res) and T47D Res shSCR, shIL-6 #1, and shIL-6 #2 cells treated with or without 1 μM palbociclib every 3 days for 6 days. Quantification of SA-βgal+ cells was calculated at day 6 relative to number of cells. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Palbociclib isethionate (MedChemExpress) was diluted in 0.5 W/V% methyl cellulose 400 (FUJIFILM Wako Chemicals), TTI-101 was diluted in 60:40 Labrasol:PEG400 with brief sonication for about 2 min, and vehicle was a 50:50 mixture of 0.5 W/V% methyl cellulose 400 and 60:40 Labrasol:PEG400.

Techniques: Control, shRNA, Concentration Assay, Knockdown, Enzyme-linked Immunosorbent Assay, Staining

Journal: NPJ Precision Oncology

Article Title: IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer

doi: 10.1038/s41698-025-01041-1

Figure Lengend Snippet: A , B Fold change in the tumor volume in female nude mice bearing either PR-1 ( A ) or PR-4 ( B ) after treatment with combination of palbociclib (palbo) with TTI-101, and vehicle up to 74 days (PR-1) and 52 days (PR-4). The Tukey multiple comparisons test determined p values. C , D Relative change in tumor volume at the treatment endpoint for PR-1 ( C ) and PR-4 ( D ) for each individual mouse. E , F Event-free survival analysis of PR-1 ( E ) and PR-4 ( F ) PDX models treated as described in A-B, calculated based on the days on treatment when fold change in tumor volume reached 1.5 (PR-1) or 7 (PR-4). The Mantel-Cox log-rank test determined p values. G , H Quantification (left panel) and representative images (right panel) of Ki67 immunohistochemical staining at the treatment endpoint. The Tukey multiple comparisons test determined p values. I , J White blood cell count (WBC), red blood cell count (RBC), and neutrophils measured from blood collected at the treatment endpoint. Gray area indicates normal ranges for non–tumor-bearing female nude mice. K , L Change in body weight at the indicated days over the course of treatment. M , N Level of TTI-101 accumulation (ng/g) evaluated by LC-MS/MS in tumor lysates collected 4 h after the last drug was administered at the treatment endpoint in PR-1 and PR-4. ND=not detected. O . Quantification (left panel) and representative images (right panel) of pSTAT3 (Y705) immunohistochemical staining at treatment end point with the indicated treatments. Tukey’s multiple comparisons test determined p -values. * p < 0.05. P , Q Luminex analysis of tumor lysates for pSTAT3 and STAT3 at treatment end point with the indicated treatments in PR-1 (P) and PR-4 (Q). MFI = Mean Fluorescent Intensity, * p < 0.05, tumor lysates were normalized to 1ug/uL. R Tumor human IL-21 (hIL-21) levels as measured by the ProcartaPlex Human Immune Monitoring 65-plex Luminex analysis of PR-1 and PR-4 PDX tumor lysate samples collected at the treatment endpoint. S Hierarchical clustering heat map with the z-scores of significant differentially expressed proteins with adjusted p < 0.3 between combination (Palbo+TTI-101) and vehicle from reverse-phase protein array analysis of PR-1 PDX tumor lysates collected at the treatment endpoint. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Palbociclib isethionate (MedChemExpress) was diluted in 0.5 W/V% methyl cellulose 400 (FUJIFILM Wako Chemicals), TTI-101 was diluted in 60:40 Labrasol:PEG400 with brief sonication for about 2 min, and vehicle was a 50:50 mixture of 0.5 W/V% methyl cellulose 400 and 60:40 Labrasol:PEG400.

Techniques: Immunohistochemical staining, Staining, Cell Characterization, Liquid Chromatography with Mass Spectroscopy, Luminex, Protein Array